/
Respiratory
Pulmonary Fibrosis
48
Pipeline Programs↗
82
Active Trials↗
58
Companies Involved↗
Pulmonary Fibrosis is a moderately active landscape with 48 programs across 58 companies. The most active players are Bristol-Myers Squibb, Guangdong Hengrui Pharmaceutical Co., Ltd, Avalyn Pharma Inc.. 11 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical7
Phase 14
Phase 226
Phase 311
Approved
No programs
Analysis
Modality Breakdown
90%
Small molecule
36 of 40 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 40 classified programs, each share of the total. Modality classified for 88% of 48 pipeline programs.
Analysis
Trial Status
291
clinical trials
Completed142 · 49%
Recruiting50 · 17%
Terminated33 · 11%
Unknown status22 · 8%
Active, not recruiting15 · 5%
Not yet recruiting15 · 5%
Other14 · 5%
Clinical Trials
Trial Activity
291 trials
Page 1 of 20
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)